BMS
Bristol Myers Squibb, Medic Life Sciences Collaborate on Tumor Target Discovery
Medic will receive upfront payments and will be eligible for additional option payments, as well as future development and regulatory milestone payments.
Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug
The companies are working to establish FoundationOne CDx as a companion diagnostic for BMS's investigational tyrosine kinase inhibitor repotrectinib.
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Premium
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Rancho Biosciences Launches Single-Cell Data Science Consortium With Pharma Firms
BMS, J&J, Novartis, and Vesalius will work with the bioinformatics firm to develop standards for creating and using single-cell datasets for drug discovery.